# Faeve, LLC 

America's First FDA OTC Monograph Platform Built Entirely From Plants

- Canonical URL: https://wefunder.com/faeve.llc.
- Entity ID: wefunder:company:189442
- Last updated: 2026-09-14T23:53:22Z
- Generated at: 2026-09-15T05:06:23Z

## Quick facts
- Only FDA OTC botanical plant based analgesic in the US. NDC code issued.
- $500k in predecessor sales before any outside investment.
- Warm retail network, entering on our terms.
- Ahead of competition and creating new landscape with understanding of plant active.

## Active fundraises
- wefunder:fundraise:161630: 4(a)(6) open (USD)

## Story
Subject: Faeve Is Open! Get In Before the Shelves Do!Investors,America's first FDA OTC monograph platform built entirely from plants is raising equity. Right now.This isn't a concept. Faeve has navigated the FDA OTC pathway. You know, the regulatory gauntlet that eliminates most plant-based brands before they start. We completed seven formula revisions, secured a labeler code and NDC filing, and days from being forward-facing with the FDA. A 2,500-unit launch run is production-ready. Amazon and national retail conversations are already live.Seven products are mapped across the roadmap. Kevo-Prophen, our analgesic, launches Q2 2026. The category doesn't exist yet. We're building it.Why this moment:FDA OTC compliant — a barrier almost no plant-based brand ever clearsLabeler code issued, NDC filed as 87607-001-01 — real infrastructure, in placeManufacturing locked, launch run readyRetail buyer conversations already underway$6M pre-money valuation on a Wefunder raise with $100 minimum entryThere is a specific window in early-stage companies where risk has been meaningfully reduced but valuation hasn't caught up to future distribution. That window closes the moment retail does.Every dollar raised converts to equity ownership. Not perks. Not product discounts — you have those for life. A stake in the company that owns this category.Data Room is open: financials, regulatory documentation, manufacturing strategy, market positioning, launch modeling.The round will not stay open indefinitely.Plant medicine is entering its regulated era. Faeve is already there.— Meredith Founder, Faeve | meredith.murdock@faeveusa.com | 352-446-6175

## Team
- Meredith Murdock (Founder)
- Libia F. Scheller, PhD, MBA (Executive Advisor)
- Salvatore Buscemi (Investor Advisor)
- Prabodh Satyal, PhD (Scientific Advisor)
- Hana Tisserand (Safety Advisor)
- Heather O'Brien (Marketing Advisor)
- Brent Hauver (Business Development Advisor)
- Stephen Adler, JD (Legal Advisor)
- Kelly Ablard, PhD (Sustainability Advisor)